Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A1EWVY8
Mon, 27.11.2023
Formycon AG
Press Release // November 27, 2023
Formycon announces EMA submission for FYB203, a biosimilar candidate to Eylea® (Aflibercept)
Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and its license partner Klinge Biopharma GmbH (Klinge) announce that the marketing authorization application (MAA) for FYB203, a biosimilar candidate for Eyle [ … ]
Mon, 13.11.2023
Formycon AG
Press release // November 13, 2023
Formycon publishes nine-month results for 2023
Development of the biosimilar portfolio is progressing according to plan – further news flow expected by the end of 2023
More than 200,000 doses of FYB201 now administered to patients worldwide
Group revenue rises to a total of € 60.2 million (Q3/2022: € 28.2 mil [ … ]
Fri, 10.11.2023
Formycon AG
Press Release // November 10, 2023
Formycon hosts conference call on nine-month figures 2023 and presents at further investor conferences
Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) will introduce the company's development and nine-month figures 2023 in a conference call on November 13, 2023.
The conference call, streamed live on the [ … ]
Tue, 10.10.2023
Formycon AG
Press Release // October 10, 2023
Formycon Ranibizumab Biosimilar FYB201/CIMERLI®1 achieved 25% market share2 in the United States
Munich – Formycons commercialization partner Coherus BioSciences, Inc. announced that sales of CIMERLI® (ranibizumab-eqrn) to retinal specialists in the United States of America (“U.S.”) have exceeded 100,000 doses si [ … ]
Fri, 29.09.2023
Formycon AG
Press Release // September 29, 2023
Formycon and Fresenius Kabi announce European Medicines Agency Acceptance of the Marketing Authorization Application for FYB202, an Ustekinumab Biosimilar Candidate
Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and its commercialization partner Fresenius Kabi today announced that the European Medicines [ … ]
Wed, 30.08.2023
Formycon AG
Press Release // August 30, 2023
Formycon reports successful first half of 2023
Development of biosimilar candidates proceeds successfully and according to plan
€ 43.8 million represent highest group revenue in Formycon’s history (+148%) partly due to significant success payments for FYB202 as well as participation in the marketing proceeds of F [ … ]
Tue, 29.08.2023
Formycon AG
Press Release // August 29, 2023
Formycon announces File Acceptance for FYB203, a biosimilar candidate to Eylea®1 (aflibercept), by the U.S. Food and Drug Administration (FDA)
Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and its license partner Klinge Biopharma GmbH (“Klinge”) announce that the U.S. Food and Drug Administration (“FDA”) [ … ]
Wed, 23.08.2023
Formycon AG
Press Release // August 23, 2023
Formycon hosts conference call on financial
and earnings position for H1 2023
Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) today announced details of its financial and earnings conference call for the first half of 2023. Following the publication of the half-year report 2023 in the morning of Augus [ … ]
Mon, 07.08.2023
Formycon AG
Press Release // August 7, 2023
Formycon and Fresenius Kabi secure U.S. License Date for proposed Ustekinumab Biosimilar
Formycon and Fresenius Kabi entered into a settlement agreement with Johnson & Johnson concerning FYB202, a proposed ustekinumab biosimilar in the U.S.
As per the settlement, FYB202 can be marketed in the U.S., subject to [ … ]
Wed, 26.07.2023
Formycon AG
Press release // July 26, 2023
Formycon reports on the regular Annual General Meeting
Shareholders approve all agenda items
Management board and supervisory board ratified by large majority
Wolfgang Essler elected as a new member to the supervisory board
Comprehensive reporting by the management on company development
Munich - On July 25, 2023 [ … ]